Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Posts Earnings Results, Misses Expectations By $0.01 EPS

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01), FiscalAI reports. The business had revenue of $19.56 million for the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%.

Here are the key takeaways from Senseonics Holdings, Inc. Common Stock’s conference call:

  • Q3 revenue more than doubled year over year to a record $19.6 million, led by U.S. growth of about 160%. Senseonics raised 2026 revenue guidance for the third time, to $68 million–$70 million from $62 million–$66 million.
  • Commercial indicators were strong: the company reported record new patient starts, active prescribers increased more than 90% year over year, and about nine in 10 new insertions came from patients switching from competing sensors. Management said reorder rates are ahead of plan.
  • Senseonics expects to launch its Eversense 365 integration with Beta Bionics’ iLet system in the coming weeks, adding to its existing Sequel/twiist partnership. Management said it expects to be a $100 million revenue company in 2027, though formal guidance will come early next year.
  • The company began human testing of Freedom, a planned CGM with no on-body component, and is targeting a pivotal study in 2027 and potential launch in 2028. These remain forward-looking milestones; the current study is an early-feasibility evaluation.
  • Despite gross margin improving to about 62%, Q3 net loss widened to $32.7 million from $19.5 million a year earlier. Full-year operating expenses are expected to be slightly above the prior $150 million–$160 million range, and cash utilization is forecast at about $120 million; management expects cash-flow breakeven shortly after Freedom launches.

Senseonics Holdings, Inc. Common Stock Trading Up 14.1%

Shares of Senseonics Holdings, Inc. Common Stock stock traded up $1.21 on Monday, hitting $9.80. The stock had a trading volume of 970,930 shares, compared to its average volume of 669,587. The company has a quick ratio of 6.40, a current ratio of 6.74 and a debt-to-equity ratio of 0.62. Senseonics Holdings, Inc. Common Stock has a one year low of $4.79 and a one year high of $10.64. The stock has a market cap of $409.67 million, a price-to-earnings ratio of -4.39 and a beta of 1.04. The stock’s 50-day simple moving average is $9.12 and its two-hundred day simple moving average is $7.26.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas Roeder purchased 13,953 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was bought at an average price of $8.98 per share, with a total value of $125,297.94. Following the completion of the purchase, the director directly owned 171,191 shares of the company’s stock, valued at $1,537,295.18. The trade was a 8.87% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.70% of the company’s stock.

Institutional Trading of Senseonics Holdings, Inc. Common Stock

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Senseonics Holdings, Inc. Common Stock during the 2nd quarter valued at approximately $15,867,000. Bank of America Corp DE bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth approximately $2,241,000. Masters Capital Management LLC lifted its stake in shares of Senseonics Holdings, Inc. Common Stock by 100.0% in the 1st quarter. Masters Capital Management LLC now owns 500,000 shares of the company’s stock valued at $3,330,000 after purchasing an additional 250,002 shares during the period. Readystate Asset Management LP purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the 2nd quarter valued at approximately $574,000. Finally, Penn Capital Management Company LLC purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the 2nd quarter valued at approximately $535,000. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SENS has been the topic of several recent analyst reports. Wall Street Zen raised Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings raised Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Barclays assumed coverage on shares of Senseonics Holdings, Inc. Common Stock in a research report on Wednesday, October 7th. They issued an “equal weight” rating and a $10.00 price objective on the stock. Mizuho lowered their target price on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Finally, TD Cowen reiterated a “buy” rating and set a $15.00 target price on shares of Senseonics Holdings, Inc. Common Stock in a research report on Tuesday, October 27th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.00.

View Our Latest Research Report on SENS

About Senseonics Holdings, Inc. Common Stock

(Get Free Report)

Senseonics Holdings, Inc is a medical technology company focused on developing and commercializing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its CGM technology is designed to measure glucose levels continuously through a small sensor inserted under the skin, with readings transmitted to an external smart transmitter and mobile application.

The company’s primary product is the Eversense CGM system. Unlike many conventional CGM systems that use an externally worn sensor, Eversense uses an implantable sensor and a removable, rechargeable transmitter worn over the sensor site.

See Also

Earnings History for Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS)

Receive News & Ratings for Senseonics Holdings Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.